Search

Finance

Cramer's View on Clover Health, UnitedHealth, and CVS

Nouriel Roubini
By Nouriel Roubini
·5 min read
This article examines Jim Cramer's analysis of Clover Health (CLOV) in comparison to UnitedHealth (UNH) and CVS, as discussed on his show, "Mad Money." It explores his perspective on CLOV as a speculative investment versus the long-term stability offered by healthcare industry leaders.

Navigating the Market: Speculation vs. Stability in Healthcare Stocks

Cramer's Initial Assessment of Clover Health

During a segment on "Mad Money," financial commentator Jim Cramer offered his insights into Clover Health Investments, Corp. (CLOV), highlighting its status as a speculative investment. He underscored the importance of focusing on a stock's future potential rather than its historical performance.

Clover Health's Financial Performance and Cramer's Re-evaluation

A caller referenced Cramer's earlier characterization of Clover Health as speculative, noting the company's reported GAAP profitability in the first quarter of 2026 and its positive full-year profitability projections. Cramer acknowledged the validity of this point, conceding that his previous assessment might have been overly cautious.

Cramer's Preference for Established Healthcare Leaders

Despite Clover Health's recent financial improvements, Cramer reiterated his stronger preference for industry stalwarts like UnitedHealth and CVS. He emphasized that these companies offer more reliable long-term investment opportunities due to their established market positions and consistent performance.

Clover Health's Business Model and Market Dynamics

Clover Health Investments, Corp. specializes in providing preferred provider organization and health maintenance organization Medicare Advantage plans. Additionally, the company offers a software platform, Clover Assistant, which assists physicians in detecting, identifying, and managing chronic conditions. Despite its innovative approach, Cramer cautioned about the company's past quarter, which he described as not particularly strong, implying that its recent upward movement should be viewed with some skepticism.

Strategic Investment Choices: Beyond Speculation

While acknowledging the potential of speculative stocks such as Clover Health, the broader investment advice suggests considering companies with less downside risk and higher upside potential, particularly in emerging sectors like AI. The discussion implicitly encourages investors to look for robust opportunities that align with significant market trends, including those influenced by trade policies and domestic manufacturing shifts.

Related Articles